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Abstract
Background: Non-standard hypertrophy of the adrenal cortex is a rare endocrinopathy causing the incidence of hyperandrogenism 
among women of procreative age.
The primary objective of this paper is the specification of the clinical picture and modifications of the concentration of pituitary, ovarian 
and adrenal hormones in the blood of female patients with the syndrome of non-standard hypertrophy of the adrenal cortex (NPKN).
Material and methods: In the Gynaecological Endocrinology Clinic of the Silesian Medical University in Katowice, Poland, 2,353 female 
patients were hospitalised between 1 January 2003 and 30 June 2009 with symptoms of hyperandrogenism. Of these, 55 were selected for 
the study. Eventually, 25 female patients with diagnosed NPKN, and 30 randomly selected patients with the polycystic ovarian disease 
polycystic ovary syndrome (PCOS) were enrolled in the study. 
Results: Of the 2,353 female patients hospitalised in the Gynaecological Endocrinology Clinic with symptoms of hyperandrogenism be-
tween 1 January 2003 and 30 June 2009, NPKN was found in 1.2% of them. Patients with NPKN displayed a strong hirsutism, which was 
significantly more intense than in the comparative group. Insulin resistance was found more frequently in the group of female patients 
with PCOS (67%) compared to the group with NPKN (40%). Polycystic ovarian disease was more frequently observed in the group of 
patients with PCOS (93%), compared to the group with NPKN (72%). The average concentration of androstendione in the blood serum 
in the group of patients with NPKN amounted to 7.60 ng/ml (SD = 3.57) and was significantly higher than in the group of patients with 
PCOS where it was 3.46 ng/ml (SD = 1.53). The average concentration of free testosterone in the blood serum in the group of patients 
with NPKN amounted to 7.30 pg/ml (SD = 4.13) and was significantly higher than in the group of patients with PCOS, where it was 2.90 
pg/ml (SD =1.43 ). The average concentration of DHEAS in the blood serum in the group of patients with NPKN accounted for 403.23 μg/dl 
(SD = 192.59), and in the group with PCOS it was 257.39 μg/dl (SD = 63.67). This concentration was statistically significantly higher in the 
group with NPKN than in the group with PCOS. The average concentration of estradiole in the blood serum in the group with NPKN 
amounted to 111.98 pg/ml (SD = 113.68), while in the group with PCOS it was 62.39 pg/ml (SD = 31.18). The difference of concentrations 
between the groups NPKN and PCOS was statistically significant. We found a positive correlation between the 17-OHP concentration 
after 60 minutes of the ACTH test and the severity of hirsutism in the group of patients with NPKN (r = 0.77896). In addition, we found 
a correlation between the free testosterone and the 17-OHP concentration after 60 minutes of the ACTH test in the group of patients 
with NPKN (r = 0.48149). A positive correlation was also reported between the symptom of hypertrophy of the clitoris and the 17-OHP 
concentration after 60 minutes of the ACTH stimulation test in the group of patients with NPKN (r = 0.77221).
In the comparative group of patients with PCOS, there was no correlation between the free testosterone and 17-OHP concentration after 
60 minutes of the ACTH test (r = 0.3059). There was also no correlation between the severity of hirsutism and the concentration of 17-OHP 
concentration analysed after 60 minutes of the ACTH test. In all female patients from the PCOS group, there was a correct size of clitoris.
Conclusions: Analysing the clinical picture of the examined population of patients with NPKN enabled us to specify symptoms of disease 
which were significant for diagnosis, and which helped differentiate NPKN from other endocrinopathies involving hyperandrogenism, 
including in particular PCOS. Taking everything into consideration, non-standard hypertrophy of the adrenal cortex is a rare cause of 
hyperandrogenism in women of procreative age. Intense hirsutism and features of virilisation presenting as hypertrophy of the clitoris 
predominate in the clinical picture of non-standard hypertrophy of the adrenal cortex. 
The laboratory confirmation of diagnosis of NPKN constitutes the analysis of the 17-OHP level in blood in the ACTH stimulation test. The 
analyses of free testosterone and its unbound fraction, androstendione and estradiole, help differentiate NPKN from polycystic ovarian 
disease. (Pol J Endocrinol 2011; 62 (3): 230–237)
Key words: non-standard hypertrophy of the adrenal cortex, ACTH test, 21-hydroxylase, 17-hydroxyprogesteron, polycystic ovarian disease, 
hypertrophy of the clitoris
Streszczenie
Wstęp: Nieklasyczny przerost kory nadnerczy jest rzadką endokrynopatią powodującą wystąpienie hiperandrogenizmu u kobiet w wieku 
rozrodczym. Celem pracy jest ustalenie obrazu klinicznego i  zmian stężeń hormonów przysadkowych, jajnikowych i nadnerczowych we 
krwi pacjentek z zespołem nieklasycznego przerostu kory nadnerczy (NPKN).
Materiał i metody: W Klinice Endokrynologii Ginekologicznej Śląskiego Uniwersytetu Medycznego w Katowicach hospitalizowano 2353 
pacjentki z objawami hiperandrogenizmu w okresie od 01.01.2003–01.07.2009 r. Spośród nich do badań zakwalifikowano 55 kobiet. Ostatecz-
nie  do badań włączono 25 pacjentek z rozpoznanym NPKN i 30 wybranych losowo pacjentek z zespołem policystycznych jajników (PCOS). 
Grzegorz Franik MD, Gynaecological Endocrinology Clinic of the Silesian Medical University in Katowice, Poland, ul. Medyków 14, 
40–752 Katowice, e-mail: gfranik@poczta.onet.pl
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Wyniki: W liczbie 2353 pacjentek hospitalizowanych w Klinice Endokrynologii Ginekologicznej z objawami hiperandrogenizmu w okresie 
od 01.01.2003–01.07.2009 r. NPKN wystąpił u 1,2% z nich. U pacjentek z NPKN odnotowano silny hirsutyzm, istotnie bardziej nasilony 
niż w grupie porównawczej. Insulinooporność występowała częściej w grupie pacjentek z PCOS (67%) w porównaniu z grupą z NPKN 
(40%). Obraz policystystyczności jajników częściej obserwowano w grupie pacjentek z PCOS (93%) w porównaniu z grupą z NPKN 
(72%). Średnie stężenie androstendionu w surowicy krwi w grupie z NPKN wynosiło 7,60 ng/ml (SD = 3,57) i było istotnie wyższe niż 
w grupie z PCOS, w której wynosiło 3,46 ng/ml (SD = 1,53). Średnie stężenie  testosteronu wolnego w surowicy krwi w grupie z NPKN 
wynosiło 7,30 pg/ml (SD = 4,13) i było istotnie wyższe niż w grupie z PCOS, w której to wynosiło 2,90 pg/ml (SD = 1,43 ). Średnie stężenie 
DHEAS w surowicy krwi w grupie z NPKN wynosiło 403,23 μg/dl (SD = 192,59), a w grupie z PCOS 257,39 μg/dl (SD = 63,67). Stężenie to 
było istotnie statystycznie wyższe w grupie z NPKN niż PCOS. Średnie stężenie estradiolu w surowicy krwi w grupie z NPKN wynosiło 
111,98 pg/ml (SD = 113,68), a w grupie z PCOS 62,39 pg/ml (SD = 31,18). Różnica stężeń pomiędzy grupami z NPKN i PCOS była istotna 
statystycznie.  Stwierdzono dodatnią korelację pomiędzy stężeniem 17OHP w 60. minucie trwania testu z ACTH a nasileniem hirsutyzmu 
w grupie pacjentek z NPKN (r = 0,77896). Ponadto stwierdzono  korelację pomiędzy stężeniami wolnego testosteronu i 17OHP badanego 
w 60. minucie trwania testu z ACTH w grupie pacjentek z NPKN (r = 0,48149). Dodatnią korelację wykazano również pomiędzy objawem 
przerostu łechtaczki a stężeniem 17OHP w 60. minucie trwania testu stymulacyjnego z ACTH w grupie pacjentek z NPKN (r = 0,77221).
W grupie porównawczej pacjentek z PCOS nie wykazano korelacji pomiędzy stężeniami wolnego testosteronu i 17OHP badanego w 60. 
minucie trwania testu z ACTH (r=0,3059). Brak było także korelacji pomiędzy nasileniem hirsutyzmu a stężeniem 17OHP oznaczonego 
w 60. minucie trwania testu z ACTH. U wszystkich pacjentek z grupy PCOS odnotowano prawidłowe wymiary łechtaczki. 
Wnioski: Analiza obrazu klinicznego badanej populacji pacjentek z NPKN pozwoliła wytypować istotne dla rozpoznania objawy choro-
bowe, pomocne w różnicowaniu choroby z innymi endokrynopatiami przebiegającymi z hiperandrogenizmem, w tym głównie z PCOS. 
Podsumowując, nieklasyczny przerost kory nadnerczy jest rzadką przyczyną hiperandrogenizacji kobiet w okresie rozrodczym. W obrazie 
klinicznym nieklasycznego przerostu kory nadnerczy dominuje silnie nasilony hirsutyzm oraz cechy wirylizacji pod postacią przerostu 
łechtaczki. Potwierdzeniem laboratoryjnym rozpoznania nieklasycznego przerostu kory nadnerczy jest oznaczenie stężenia 17-OHP we 
krwi w teście stymulacyjnym z ACTH. Pomocnymi w różnicowaniu zespołu nieklasycznego przerostu kory nadnerczy z zespołem poli-
cystycznych jajników są oznaczenia wolnego testosteronu i jego niezwiązanej frakcji, androstendionu i estradiolu.
(Endokrynol Pol 2011; 62 (3): 230–237)
Słowa kluczowe: nieklasyczny przerost kory nadnerczy, test z ACTH, 21-hydroksylaza, 17-hydroksyprogesteron, zespół policystycznych jajników, 
przerost łechtaczki
Introduction
Hyperandrogenism affects between 7% and 12% of 
women of procreative age [1]. In most young women, 
hyperandrogenism is linked to polycystic ovarian dis-
ease (PCOS). Other causes of incidences of disorders 
occur much more rarely.  The mutation of the gene 
CYP21, transmitted by around 0.1% of the overall 
white population, is responsible for the prevalence 
of NPKN, also known as ‘late revealing syndrome of 
hypertrophy of the adrenal cortex’ or  ‘partial syn-
drome’ or ‘weakened syndrome’. Mutations lead to 
an enzymatic defect which results in a deficiency of 
21-hydroxylase. Clinical manifestations of the syn-
drome remain in close correlation with the grade of 
deficiency of 21-hydroxylase. On the basis of clinical 
manifestations, determining of the genotype is not 
possible, and the diversity of phenotypes indicates 
the influences of factors modifying the gene func-
tions. NPKN is an autosomal recessive disease and the 
clinical presentation of this disease varies.
The primary objective of this paper was to specify 
the clinical presentation and modifications profile 
of concentrations of pituitary, ovarian and adrenal 
hormones in the blood of female patients with the 
syndrome of non-standard hypertrophy of the adrenal 
cortex (NPKN). It was assumed that the clinical presen-
tation of NPKN is similar to that of PCOS and, accord-
ingly, the comparative group comprising women with 
this syndrome was included in this study.
Material and methods
In the Gynaecological Endocrinology Clinic of the 
Silesian Medical University in Katowice, Poland, 2,353 
female patients were hospitalised between 1 January 
2003 and 30 June 2009 with symptoms of hyperandro-
genism. Of these, 55 women were selected for inclusion 
in the study. Inclusion criteria were: female patients 
aged between 18 and 33, a NPKN diagnosis and a PCOS 
syndrome diagnosis. According to expert opinion, 
NPKN is diagnosed when: 
—  clinical symptoms of hyperandrogenisation;
—  family history includes incidents of classic hypertro-
phy of the adrenal cortex;
—  membership of ethnic groups carrying a high degree 
of risk;
—  increased level of 17-OHP (> 10 ng/ml) in the morn-
ing hours;
—  increased concentration of 17-OHP in the blood after 
corticotrophin stimulation (ACTH) (≥ 10 ng/ml after 
60 test minutes) [2]. 
Finally, NPKN was diagnosed in 28 female patients, 
of whom 25 were selected for study. The other three 
patients were excluded from analysis because they met 
exclusion criteria. PCOS was diagnosed in 2,046 female 
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patients based on the ESHRE/ASRM criteria devised in 
Rotterdam in 2003 [3]. 
For our study, 30 PCOS patients were selected by 
means of a digital number generator based on a com-
puter program: StatSoft STATISTICA (data analysis 
software system), version 7.1 (www.statsoft.com).
Finally, two groups were formed: 
—  the examined group, comprising 25 women with 
diagnosed NPKN; 
—  the comparative group, comprising 30 women with 
diagnosed PCOS.
All patients were subject to a medical and gynae-
cological examination, and to a USG examination of 
the pelvis minor. The profiles of glycaemia, insulin 
resistance and lipidogram were analysed among all of 
them, and anthropometric examinations (height, body 
mass and BMI evaluation, measurement of clitoris) were 
carried out. Rates of glucose and insulin concentration 
carried on an empty stomach were used to evaluate 
insulin resistance: Homeostasis Model Assessment 
(HOMA), Quantitative Insulin Sensitivity Check Index 
(QUICKI) and the glucose/insulin rate (G/I). The exam-
ined patients from both groups did not differ in terms of 
age: the average age of NPKN patients was 24.4 years, 
and of patients with PCOS it was 23.97 years. 
Hormonal examinations were conducted on 
an empty stomach within the first five days of the 
oestrous cycle. In blood serum, FSH, LH, PRL, TSH 
and cortisole were determined. The determination 
of androstendione and 17a-hydroxyprogesterone 
(17-OHP) in the blood serum was carried out by means 
of the ELISA method using ready sets (IBL). DHEAS 
was determined in the blood serum by means of the 
immunofluorescence method on a DPC Immuno-lite 
2000 analyser. The determination of free testosterone 
in the blood serum was carried out by means of the 
ELISA method using ready sets (DRG). The radioim-
munologic studies were conducted in the Radiodiag-
nostic and Nuclear Medicine Institute of the Silesian 
Medical University in Katowice, Poland. 
For the analysis of the present work, the following 
determinations were used: androstendione, DHEAS, 
free testosterone and 17-OHP. The results of the remain-
ing analyses served for the determination of diagno-
sis. In female patients, among whom in the morning 
hours in the first five days of the oestrous cycle, 17-OHP 
concentration amounted to ≥ 1.7 ng/ml, an ACTH 
stimulation test was conducted. This was carried out 
by intravenous application of 0.25 mg/ml of Synasthen 
(Novartis Pharma) with blood samples taken shortly 
before, and 30 and 60 minutes after, the hormone was 
injected. 17-OHP was determined from all samples., and 
a 17-OHP concentration after 60 minutes of 10 ng/ml or 
more was the basis for a diagnosis of NPKN. 
All results were subject to statistical analysis, which 
was carried out using StatSoft STATISTICA program. 
Because the parametric test comparing mean values, the 
t-Student test, requires a conformity with normal distri-
bution and variance homogeneity, the Mann-Whitney 
U-test was used.
Findings
Of the 2,353 female patients hospitalised in the Gy-
naecological Endocrinology Clinic with symptoms 
of hyperandrogenism between 1 January 2003 and 
30 June 2009, NPKN was diagnosed in 28 patients, 
meaning 1.2% of all hospitalised patients showed 
symptoms of hyperandrogenism. Among the female 
patients with NPKN, a severe hirsutism was observed, 
significantly more intense than in the comparative 
group (Table I).
In the group of NPKN patients, there was a greater 
percentage of corpulence and adiposis than in the 
group of PCOS patients. The BMI indicators were 
within normal limits in both groups, and differences 
were not statistically significant. In the group of PCOS 
patients, insulin resistance was found in 67% of patients, 
whereas in the NPKN group it was 40%. In the NPKN 
group, symptoms of polycystic ovaries were found in 
72% of patients, and in the PCOS group the figure was 
93%. The average concentrations of examined steroid 
hormones in the blood, and differences between the 
groups of patients with NPKN and PCOS, are presented 
in Table II.
The average concentration of androstendione in 
the blood serum in the NPKN group amounted to 
7.60 ng/ml (SD = 3.57) and was significantly higher 
compared to the PCOS group, where it accounted for 
3.46 ng/ml (SD = 1.53). The average concentration of 
free testosterone in blood serum in the group with 
Table I. Concentration of hirsutism among patients of the 
examined and comparative groups
Tabela I. Nasilenie hirsutyzmu u pacjentek z grupy badanej 
i porównawczej
Number 
Average concentration  
of hirsutism  
(acc. to Ferriman-Gallwey 
score)
Examined group 
with NPKN 25
23 
(SD = 7.06 )
Comparative group 
with PCOS 30
11.27 
(SD = 3.25 )
Difference of mean 
values –11.73
U-M-W Test p = 0.001
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NPKN was 7.30 pg/ml (SD = 4.13) and was signifi-
cantly higher compared to the PCOS group, where 
it was 2.90 pg/ml (SD = 1.43). The average concen-
tration of DHEAS in the blood serum of the group 
with NPKN amounted to 403.23 μg/dl (SD = 192.59), 
and in the group with PCOS it was 257.39 μg/dl 
(SD = 63.67). This concentration was significantly 
higher in the group with NPKN then in the PCOS 
group. The average concentration of estradiole in 
the blood serum in the NPKN group accounted for 
111.98 pg/ml (SD = 113.68) and in the group with 
PCOS it was 62.39 pg/ml (SD = 31.18). This difference 
was statistically significant. The average 17-OHP 
concentrations in the ACTH stimulation test are 
presented in Table III.
We found a positive correlation between the 17-OHP 
concentration after 60 minutes of the ACTH test and 
the severity of hirsutism in the group of patients with 
NPKN (r = 0.77896) (Figure 1).
In addition, we found a correlation between the free 
testosterone and 17-OHP concentrations examined after 
60 minutes of the ACTH test in the group of patients 
with NPKN (r = 0.48149) (Figure 2).
A positive correlation was also found between the 
symptom of hypertrophy of the clitoris and the 17-OHP 
concentration after 60 minutes of the ACTH stimulation 
test in the group of patients with NPKN (r = 0.77221) 
(Figure 3).
We did not find a correlation between the free tes-
tosterone and 17-OHP concentrations examined after 
60 minutes of the ACTH test in the group of patients 
with PCOS (r = 0.3059). 
There was also no correlation between severity of 
hirsutism and the 17-OHP concentration determined 
after 60 minutes of the ACTH test in the group of pa-
tients with PCOS. Among all patients from the PCOS 
group, we found correct clitoris dimensions.
Discussion
Non-standard hypertrophy of the adrenal cortex 
(NPKN) belongs to a group of rare diseases which are 
characterised by an overproduction of androgens [4–8]. 
According to several authors, less than 5% of women 
with excessive androgens suffer from non-standard 
hypertrophy of the adrenal cortex in the general 
population [9]. Moran et al. [10] stated that NPKN 
dependent on a deficiency of 21-hydroxylase is the 
most frequent autosomal recessive disease, occurring 
in 1/1,000–2,000 of the whole population excluding 
Ashkenazi Jews. Azziz et al. [4] pointed out the ethnic 
groups at a high degree of risk, among which 17-OHP 
Table II. Average concentrations of examined steroid hormones and differences of mean values between the groups
Tabela II.  Średnie stężenia badanych hormonów steroidowych i różnice średnich pomiędzy grupami 
Examined group 
with NPKN
Control group  
with PCOS
Difference of mean 
values
Statistical  
significance
Average concentration 
of androstendione
7.60 ng/ml 
(SD = 3.57)
3.46 ng/ml 
(SD = 1.53) –4.15 ng/ml p = 0.001
Average concentration 
of free testosterone
7.30 ng/ml 
(SD = 4.13)
2.90 pglm/l 
(SD = 1.43) –4.40 ng/ml p = 0.001
Average concentration 
of DHEAS
403.23 μg/dl 
(SD = 192.59)
257.39 μg/dl 
(SD = 63.67) –145.83 μg/dl p = 0.001
Average concentration 
of estradiole
111.98 ng/ml 
(SD = 113.68)
62.39 ng/ml 
(SD = 31.18) –49.59 ng/ml p = 0.001
Table III. Average 17-OHP concentrations in the ACTH stimulation test [ng/ml]
Tabela III. Średnie stężenia 17-OHP w teście z ACTH [ng/ml]
p = 0.001 
0 minutes 
ng/ml
p = 0.001 
30 minutes
p = 0.001 
60 minutes
X SD X SD X SD
Examined group 
with NPKN 10.48 6.52 23.96 17.73 30.40 18.77
Control group  
with PCOS 1.22 0.79 2.07 0.65 2.70 0.85
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Figure 1. Positive correlation between the 17-OHP concentration after 60 minutes of the ACTH test and the severity of hirsutism in 
the group of patients with NPKN
Rycina 1. Dodatnia korelacja pomiędzy stężeniem 17-OHP w 60. minucie trwania testu z ACTH a nasileniem hirsutyzmu w grupie 
pacjentek z NPKN
Figure 2. Correlation between the free testosterone and 17-OHP concentrations  examined after 60 minutes of the ACTH test in the 
group of patients with NPKN
Rycina 2. Korelacja pomiędzy stężeniami wolnego testosteronu i 17-OHP w 60. minucie trwania testu z ACTH w grupie 
pacjentek z NPKN
Endokrynologia Polska/Polish Journal of Endocrinology 2011; 62 (3)
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needs to be determined in order to exclude NPKN: 
Ashkenazi Jews (frequency of incidence 1/27), people 
of Spanish descent (1/140) and Slavs (1/50). This is in 
contrast to Italians (1/300) and the Caucasian popula-
tion  in the USA (1/1,000). This disease occurs rarely in 
African-Americans [4].
In the examined group of women visiting the En-
docrinology Clinic due to hyperandrogenism, mainly 
living in Upper Silesia, the incidence of NPKN was 
1/120. This seems lower than expected on the basis of 
information in the literature [4, 6, 11]. This discrep-
ancy may be explained by the fact that the non-classic 
deficiency of 21-hydroxylase is based on partial insuf-
ficiency of 21-hydroxylation, which in fact means that 
in a certain proportion of sufferers, this disease shows 
no symptoms.
Wild et al. [12, 13] reported that an increased con-
centration of testosterone can slightly disturb the lipid 
profile, and they also observed a tendency towards 
hyperinsulinaemia with a positive correlation between 
free testosterone and triglyceride concentration and 
a negative correlation with HDL cholesterol concen-
tration  [12, 13]. The authors found a high percentage 
of corpulent women in diseases accompanied by hy-
perandrogenism, including NPKN. In our own study, 
we did not find statistically relevant differences in BMI 
between the group of patients with NPKN and the 
comparative group with PCOS, although the frequen-
cy of incidence of corpulence in the NPKN patients is 
higher than in the comparative group. Consequently, 
it seems that the incidence of corpulence among fe-
male patients with accompanying hyperandrogenism 
symptoms is not a factor facilitating the identification 
of patients with NPKN. 
Insulin resistance is defined as a decreased abil-
ity to stimulate glucose conversions in target tissues, 
which leads to a compensatory increase of insulin 
concentrations in the serum. Hyperinsulinaemia can 
be found among women with hyperandrogenism 
and among corpulent women, but also among slim 
ones. Hyperinsulinaemia occurs more often, and its 
course is more difficult, among corpulent women. 
In our study, insulin resistance occurred more fre-
quently in the comparative group with PCOS than 
among patients with NPKN. This shows that although 
hyperan drogenism is more strongly expressed in 
NPKN, insulin resistance is rarer. This implies that 
androgens are not the only factor disturbing the tissue 
metabolism of insulin. 
We found in the comparative group of patients 
with PCOS that disturbances of ovary structure ob-
served in the ultrasonographical study occurred more 
Figure 3. Positive correlation between hypertrophy of the clitoris and the 17-OHP concentration after 60 minutes of the ACTH test in 
the group of patients with NPKN
Rycina 3. Dodatnia korelacja pomiędzy przerostem łechtaczki a stężeniem 17-OHP w 60. minucie trwania testu z ACTH w 
grupie pacjentek z NPKN
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frequently than in patients with NPKN. This confirms 
that polycystic symptoms  in the ovary/ovaries struc-
ture is not characteristic for patients with the examined 
syndrome.
 There is a deficiency of 21-hydroxylase enzyme 
among patients with NPKN. This deficiency causes an im-
pairment of conversion of 17α-hydroxyprogesterone 
to 11-deoxycortisole and progesterone to deoxycor-
ticosterone. As a consequence of these processes, 
androgen precursors are accumulated (including 
17α-hydroxyprogesterone and deoxycorticosterone). 
The diagnosis of deficiency of 21-hydroxylase is based 
on the measurement of concentration in the blood 
of basic 17-OHP and – again after ACTH stimulation 
[14–18]. Three types of answers are possible in the ACTH 
stimulation test: the standard answer in congenital 
hypertrophy of the adrenal cortex, where basic concen-
trations, and again after ACTH stimulation, reach the 
highest levels (> 100 ng/ml basic and > 10,000 ng/ml 
after stimulation); the intermediate answer typical of 
patients with non-standard hypertrophy of the adrenal 
cortex (≥ 10 ng/ml basic and > 10– 100 ng/ml after ACTH 
stimulation); and a characteristic answer for heterozy-
gote, where basic 17-OHP levels, and again after ACTH 
stimulation, are within normal limits. 
The symptoms of hyperandrogenism in NPKN have 
a different level and there are three phenotype vari-
ants: the first one with disturbances of ovulation and 
PCOS characteristics; the second one with hirsutism 
symptoms, with slight and infrequent periods; and the 
third one with increased androgen levels in the blood 
but without clinical symptoms [19]. 
In the examined group of patients with NPKN, we 
found statistically significant higher concentrations of 
17-OHP already in basic determinations, before carry-
ing out the ACTH test.  A characteristic of NPKN is also 
a significant concentration increase of 17-OHP in blood 
after ACTH stimulation [21]. The increased concentra-
tion of 17-OHP among some women with symptoms of 
hyperandrogenism caused by other reasons, is usually 
small, which is confirmed by findings of our results 
among women with PCOS [18, 21]. 
Biologically active androgens are 19-carbon steroids, 
of which testosterone is the strongest one. In the exam-
ined group of patients with NPKN, the average concen-
trations of free testosterone were significantly higher 
than in the comparative group of patients with PCOS. 
Similarly, the average concentrations of androstendione 
in the examined group were significantly higher than in 
the comparative group of patients with PCOS. It is to be 
assumed that among women with NPKN, the adrenal 
source of producing androgens predominates, although 
the participation of ovarian source in the overall pool of 
serous androgens cannot be ruled out. This is confirmed 
by the positive correlation between the concentration 
of free testosterone and 17-OHP after 60 minutes of 
the ACTH test. 
Hirsutism is a significant symptom of androgen sur-
plus. Among the female patients with NPKN, a severe 
hirsutism was observed, which was significantly more 
intense than that observed in the comparative group. 
This observation aligns with the information in the 
literature, where authors have emphasised that severe 
hirsu tism is caused by an adrenal defect [21–23]. 
High concentrations of androgens in the blood can 
be an isolated reason for particularly severe hirsutism 
and can lead to virilism. We observed this in our study, 
where in the examined group of patients with NPKN 
we found a positive correlation between the concen-
tration of 17-OHP after 60 minutes of the ACTH test 
and the severity of hirsutism.  A significant severity 
of hirsutism should persuade clinicians to carry out 
17-OHP determinations in the blood. Moreover, in the 
examined group of women, we found the characteris-
tics of clitoris hypertrophy in18 of 25 (72%). We found 
also a positive correlation between hypertrophy of the 
clitoris and 17-OHP concentration after 60 minutes of 
the ACTH test. These results demonstrate that adrenal 
hyperandrogenism leads to virilisation. 
The next androgen participating in the pathogenesis 
of hirsutism is sulphate of dehydroepiandrosterone 
(DHEAS). It occurs in significantly higher concentrations 
in the blood compared to other androgens, and comes 
almost exclusively from the adrenals. The determination 
of DHEAS concentration in the blood was not especially 
helpful as a screening assay in the NPKN diagnosis, 
because its level is increased among 16% of healthy 
women [4]. In the examined group of patients with 
NPKN, we found a higher DHEAS concentration in the 
blood serum compared to the group with PCOS. It is 
to be assumed that increased ACTH production among 
women with non-standard hypertrophy of the adrenal 
cortex, caused by an enzymatic synthesis deficiency 
of 21-hydroxylase, also affects the increase of DHEAS 
concentration in the blood serum. 
We also found that the average concentration 
of estradiole in the blood serum in the group with 
NPKN was higher than in the group with PCOS.  The 
difference of concentrations between the groups was 
significant. It seems that lower production of estra-
diole among women is attributed to a handicapped 
activity of aromatase in the granule cells. The adrenals 
do not produce significant numbers of oestrogenes 
in the blood; however, they increase indirectly the 
amount of the overall concentration of oestrogens by 
ex-gonadal conversion of precursors of C-19 andro-
gens into oestrogens. This mechanism certainly occurs 
among patients with NPKN, among whom adrenals 
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produce increased amounts of pre-androgens, espe-
cially 17-OHP. 
In summary, we found that the clinical manifesta-
tion of the examined population of patients with NPKN 
enabled us to specify significant symptoms of disease 
for diagnosis, which were of assistance in differentiating 
from other endocrinopathies proceeding with hyperan-
drogenism, including in particular PCOS. 
These symptoms include severe hirsutism and the 
characteristics of virilism in the form of hypertrophy of 
the clitoris. The most important factor for diagnosis is 
the increase of concentrations of 17-OHP after ACTH 
stimulation, as well as high concentrations of testoster-
one and androstendione.
The specification of the appropriate diagnosis is 
significant for medical treatment for at least two reasons: 
1. Treatment must be long-running.
2. Couples expecting offspring require genetic con-
sultation in order to establish a pre-natal diagnosis 
and potential early implementation of appropriate 
treatment of congenital hypertrophy of the adrenal 
cortex (WPN).
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